We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
13 own
8 watching
Current Price
$7.49
$-0.26
(-3.35%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
619.43M
52-Week High
24.005
52-Week Low
6.845
Average Volume
0.4M
Dividend Yield
--
P/E Ratio
--
Market Capitalization619.43M
52-Week High24.005
52-Week Low6.845
Average Volume0.4M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
1month ago
Shares of Alector, Inc. (NASDAQ:ALEC Get Rating) have received an average recommendation of Hold from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating ...
Ticker Report
1month ago
Shares of Alector, Inc. (NASDAQ:ALEC Get Rating) have received a consensus rating of Hold from the eight research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold ...
Globe Newswire
2 months ago
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ: ALEC) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. ...
Ticker Report
6 months ago
Bank of America Corp DE raised its holdings in Alector, Inc. (NASDAQ:ALEC Get Rating) by 52.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 411,008 shares of the companys stock after ...
Globe Newswire
7 months ago
NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ: ALEC), Reata Pharmaceuticals, Inc. (NASDAQ: RETA), Axsome Therapeutics, Inc. (NASDAQ: AXSM), and PTC ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$7.49
$-0.26
(-3.35%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00